Head-to-head · WeighScore
Enhance MD vs MyStart Health
The verdict
Enhance MD takes it — 84.8/100 to 67.1/100.
Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Enhance MD | MyStart Health |
|---|---|---|
| WeighScore | 84.8/100 | 67.1/100 |
| Grade | B | C |
| Scorecard rank | #11 | #168 |
| Semaglutide | $212/mo | $299/mo (all doses, compounded) |
| Tirzepatide | $280/mo | $299/mo (all doses, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #11 · B
Strengths
- Transparent tiered pricing across sema, tirz, microdose, and combo
- Dose-flat — the price does not step up as you titrate
- Six-month lab testing plus provider-led care
- NAD+ longevity adjacency available
Where it loses points
- Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
- No oral or sublingual route
- States served are not published
- Higher entry price than the cheapest compounded programs
Graded #168 · C
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
Where it loses points
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- Pharmacy partners not named, so 503A compliance can't be independently verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.